We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.215 | -0.54% | 39.795 | 40.005 | 39.675 | 39.97 | 850,270 | 15:38:31 |
From Jul 2021 to Jul 2024
By Ian Walker
GlaxoSmithKline PLC said Wednesday that it has appointed Tony Wood as chief scientific officer from August, replacing Hal Barron, who will become nonexecutive director.
The pharmaceutical giant said Mr. Wood will assume full accountability for research and development on Aug. 1.
Mr. Wood joined the company in 2017 as senior vice president, medicinal science and technology, and has more than 30 years of experience in the industry.
Mr. Barron is stepping down from the role as he has been appointed CEO and board co-chair of Altos Labs.
"Altogether, these changes provide us with a clear pathway for continued momentum in R&D to deliver our new ambitions for growth and scale impact for patients," Chief Executive Emma Walmsley said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 19, 2022 02:32 ET (07:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
